Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis and With Inadequate Response or Intolerance to Current Conventional Synthetic DMARDs or Tumor Necrosis Factor Inhibitors

Trial Profile

Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis and With Inadequate Response or Intolerance to Current Conventional Synthetic DMARDs or Tumor Necrosis Factor Inhibitors

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Jul 2018

At a glance

  • Drugs Sarilumab (Primary) ; Azathioprine; Chloroquine; Hydroxychloroquine; Leflunomide; Methotrexate; Methotrexate; Sulfasalazine
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms SariPRO
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Jun 2018 Planned End Date changed from 16 Aug 2018 to 15 Apr 2019.
    • 07 Jun 2018 Planned primary completion date changed from 16 Aug 2018 to 15 Apr 2019.
    • 06 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top